
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Your secretary receives a frantic call from the mother of one of your patients: "My son is having a seizure and we're on the way to the emergency department!"






